Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 152

Similar articles for PubMed (Select 22658808)


A nomogram to predict individual prognosis in node-negative breast carcinoma.

Mazouni C, Spyratos F, Romain S, Fina F, Bonnier P, Ouafik LH, Martin PM.

Eur J Cancer. 2012 Nov;48(16):2954-61. doi: 10.1016/j.ejca.2012.04.018. Epub 2012 May 31.


Increased risk of locoregional recurrence for women with T1-2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy.

Abdulkarim BS, Cuartero J, Hanson J, Deschênes J, Lesniak D, Sabri S.

J Clin Oncol. 2011 Jul 20;29(21):2852-8. doi: 10.1200/JCO.2010.33.4714. Epub 2011 Jun 13.


Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.

Jänicke F, Prechtl A, Thomssen C, Harbeck N, Meisner C, Untch M, Sweep CG, Selbmann HK, Graeff H, Schmitt M; German N0 Study Group.

J Natl Cancer Inst. 2001 Jun 20;93(12):913-20.


Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma.

Manders P, Tjan-Heijnen VC, Span PN, Grebenchtchikov N, Geurts-Moespot A, van Tienoven DT, Beex LV, Sweep FC.

Cancer. 2004 Aug 1;101(3):486-94.


Association between extent of axillary lymph node dissection and survival in patients with stage I breast cancer.

Sosa JA, Diener-West M, Gusev Y, Choti MA, Lange JR, Dooley WC, Zeiger MA.

Ann Surg Oncol. 1998 Mar;5(2):140-9.


Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer.

Foekens JA, Look MP, Peters HA, van Putten WL, Portengen H, Klijn JG.

J Natl Cancer Inst. 1995 May 17;87(10):751-6.


The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.

Foekens JA, Peters HA, Look MP, Portengen H, Schmitt M, Kramer MD, Brünner N, Jänicke F, Meijer-van Gelder ME, Henzen-Logmans SC, van Putten WL, Klijn JG.

Cancer Res. 2000 Feb 1;60(3):636-43.


Survival benefit of post-mastectomy radiotherapy in breast carcinoma patients with T1-2 tumor and 1-3 axillary lymph node(s) metastasis.

Duraker N, Demir D, Bati B, Yilmaz BD, Bati Y, Çaynak ZC, Sobutay E.

Jpn J Clin Oncol. 2012 Jul;42(7):601-8. doi: 10.1093/jjco/hys052. Epub 2012 Apr 17.


Is breast conservation therapy superior to mastectomy for women with triple-negative breast cancers?

Pignol JP, Rakovitch E, Olivotto IA.

J Clin Oncol. 2011 Jul 20;29(21):2841-3. doi: 10.1200/JCO.2011.35.8838. Epub 2011 Jun 13. No abstract available.


Prognostic significance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor (PAI-1) in patients with primary invasive ductal breast carcinoma - a 7.5-year follow-up study.

Jelisavac-Cosic S, Sirotkovic-Skerlev M, Kulic A, Jakic-Razumovic J, Kovac Z, Vrbanec D.

Tumori. 2011 Jul-Aug;97(4):532-9. doi: 10.1700/950.10409.


Plasminogen activator inhibitor-1 and prognosis in primary breast cancer.

Foekens JA, Schmitt M, van Putten WL, Peters HA, Kramer MD, Jänicke F, Klijn JG.

J Clin Oncol. 1994 Aug;12(8):1648-58.


Clinical and pathologic risk factors of tumor recurrence in patients with node-negative early breast cancer after mastectomy.

Lin PH, Yeh MH, Liu LC, Chen CJ, Tsui YC, Su CH, Wang HC, Liang JA, Chang HW, Wu HS, Yeh SP, Li LY, Chiu CF.

J Surg Oncol. 2013 Nov;108(6):352-7. doi: 10.1002/jso.23403. Epub 2013 Aug 31.


Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.

Lee KH, Im SA, Oh DY, Lee SH, Chie EK, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ.

BMC Cancer. 2007 Apr 12;7:63.


Plasminogen activator inhibitor type 1 is the most significant of the usual tissue prognostic factors in node-negative breast ductal adenocarcinoma independent of urokinase-type plasminogen activator.

Descotes F, Riche B, Saez S, De Laroche G, Datchary J, Roy P, André J, Bobin JY.

Clin Breast Cancer. 2008 Apr;8(2):168-77. doi: 10.3816/CBC.2008.n.018.


Identification of low-risk node-negative breast cancer patients by tumor biological factors PAI-1 and cathepsin L.

Thomssen C, Oppelt P, Jänicke F, Ulm K, Harbeck N, Höfler H, Kuhn W, Graeff H, Schmitt M.

Anticancer Res. 1998 May-Jun;18(3C):2173-80.


Prognostic importance of PAI-1 in node negative breast cancer patients--results after 10 years of follow up.

Eljuga D, Razumovic JJ, Bulic K, Petrovecki M, Draca N, Bulic SO.

Pathol Res Pract. 2011 May 15;207(5):290-4. doi: 10.1016/j.prp.2011.02.008. Epub 2011 Apr 2.


Tumor-biological factors uPA and PAI-1 as stratification criteria of a multicenter adjuvant chemotherapy trial in node-negative breast cancer.

Prechtl A, Harbeck N, Thomssen C, Meisner C, Braun M, Untch M, Wieland M, Lisboa B, Cufer T, Graeff H, Selbmann K, Schmitt M, Jänicke F.

Int J Biol Markers. 2000 Jan-Mar;15(1):73-8.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk